Swaza

It was an honor for Swaza to be on the CTA Center Stage at #CES2023 to open the Global Innovation Startup Showcase. When we think about global challenges that need focused and scalable tech solutions, we can't help but think about how respiratory illness has shaped our world for the last three years--and will continue to challenge us as new threats emerge, as global cities experience environmental stress, and as populations age. The pandemic highlighted a shocking truth: we do not have simple, effective solutions for respiratory distress. Swaza is working to change this with a revolutionary nanofluid breathing aid designed to improve oxygen delivery even in damaged lungs or in extreme conditions---all without the need for complicated equipment or invasive, expensive treatments. This technology will be an important asset for the world's medical resiliency and will save lives.  

We are proud to announce that Swaza Inc. has been selected as one of 13 companies worldwide to join DIANA’s 2025 Health and Human Performance cohort. This recognition highlights our commitment to advancing respiratory health through innovative therapeutics and materials that address critical challenges in resilience and human performance.   “This is a significant milestone for Swaza as we continue our work to redefine respiratory care,” said Niki Santo, CEO of Swaza Inc. “DIANA’s support will enable us to accelerate the development of our life-saving solutions and broaden our impact on a global scale.”   We remain committed to setting a new standard of care, addressing critical unmet needs in respiratory health, and expanding the applications of our platform across other areas, such as tissue regeneration and trauma care.   Read more here: https://lnkd.in/gaPXJDBu Watch the announcement here: https://lnkd.in/gBjHP-m4   #Innovation #RespiratoryHealth #DIANA2025 #HealthTech #SwazaInc #GlobalImpact #NanofluidTechnology

We are proud to announce that Swaza Inc. has been selected as one of 13 companies worldwide to join DIANA’s 2025 Health and Human Performance cohort. This recognition highlights our commitment to advancing respiratory health through innovative therapeutics and materials that address critical challenges in resilience and human performance.   “This is a significant milestone for Swaza as we continue our work to redefine respiratory care,” said Niki Santo, CEO of Swaza Inc. “DIANA’s support will enable us to accelerate the development of our life-saving solutions and broaden our impact on a global scale.”   We remain committed to setting a new standard of care, addressing critical unmet needs in respiratory health, and expanding the applications of our platform across other areas, such as tissue regeneration and trauma care.   Read more here: https://lnkd.in/gaPXJDBu Watch the announcement here: https://lnkd.in/gBjHP-m4   #Innovation #RespiratoryHealth #DIANA2025 #HealthTech #SwazaInc #GlobalImpact #NanofluidTechnology

Swaza had the distinct pleasure to present at the 2024 BARDA Innovation Summit where we presented our cutting edge research and development efforts. We also thank Principal Deputy Assistant Secretary and Chief Operating Officer at HHS Administration for Strategic Preparadness and Response, Nikki Bratcher-Bowman for her support of our medical countermeasure efforts.

For those of you interested in learning more about what we are building at Swaza, join us at Stanford University as we present at the Stanford Wearable Electronics Initiative (eWEAR) Health Prize Showcase. Join us and show your support for oxygen nano therapeutics.

Niki V. Santo speaking to a packed room at Marathon Fund's Applied AI in Health Event about emerging innovations in health, AI, and early stage biotech R&D.

We are thrilled to be a part of such a vibrant community of startups featured at our New York office! 🏢 (companies are listed alphabetically) As a Blue Knight company with Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA), Swaza Inc. is at the forefront of healthcare innovation. Our presence marks a significant milestone in our journey and reflects our commitment to bringing innovative solutions closer to our partners. We look forward to leveraging the opportunities that New York has to offer and are excited about the impactful work we will accomplish together. Stay tuned for updates on our upcoming initiatives and events. New York City Economic Development Corporation

We are thrilled to be a part of such a vibrant community of startups featured at our New York office! 🏢 (companies are listed alphabetically) As a Blue Knight company with Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA), Swaza Inc. is at the forefront of healthcare innovation. Our presence marks a significant milestone in our journey and reflects our commitment to bringing innovative solutions closer to our partners. We look forward to leveraging the opportunities that New York has to offer and are excited about the impactful work we will accomplish together. Stay tuned for updates on our upcoming initiatives and events. New York City Economic Development Corporation

Swaza was recognized with the People’s Choice Award at the Poster Showcase Award session at the 2024 Blue Knight Symposium. Further, we had the privilege to present our work to Dawn O'Connell, the Assistant Secretary for Preparedness and Response with the U.S. Department of Health and Human Services (HHS). A big thank you to the event organizers, Rachel Rath, and team for organizing a great event. Also a shout out to Melinda Richter and Gary Disbrow (Director of BARDA) for forming and continually supporting the BARDA x JLABS partnership.

CEO Niki V. Santo kicks off our showcase at the 2024 Blue Knight Symposium where she is highlighting the innovative research and development happening at Swaza. Blue Knight is a joint initiative between Johnson & Johnson Innovation – JLABS ('JLABS') and the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.